Sanjay Batra

Dr. Sanjay Batra

Laboratory of Pulmonary Immunotoxicology, Health Research Center, Southern University and A&M College, Baton Rouge, LA 70813, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
RBRizwana Begum
Rizwana Begum
STShilpa Thota
Shilpa Thota
AAAbubakar Abdulkadir
Abubakar Abdulkadir
GKGagandeep Kaur
Gagandeep Kaur
PBPrathyusha Bagam
Prathyusha Bagam
Sanjay BatraSanjay Batra
Sanjay Batra

28 May 2016 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Closed access
PDF file
APArvind Panday
Arvind Panday
MIMaria Eugenia Inda
Maria Eugenia Inda
PBPrathyusha Bagam
Prathyusha Bagam
MSMalaya K. Sahoo
Malaya K. Sahoo
DODiana Osorio
Diana Osorio
Sanjay BatraSanjay Batra
Sanjay Batra
The nuclear factor (NF)-κB family of transcription factors are ubiquitous and pleiotropic molecules that regulate the expression of more than 150 genes involved in a broad range of processes including inflammation, immunity, cell proliferation, differentiation, and survival. The chronic activation or dysregulation of NF-κB signaling is the central cause of pathogenesis in many disease conditions and, therefore, NF-κB is a major focus of therapeutic intervention. Because of this, understanding the relationship between NF-κB and the induction of various downstream signaling molecules is imperative. In this review, we provide an updated synopsis of the role of NF-κB in DNA repair and in various ailments including cardiovascular diseases, HIV infection, asthma, herpes simplex virus infection, chronic obstructive pulmonary disease, and cancer. Furthermore, we also discuss the specific targets for selective inhibitors and future therapeutic strategies.

25 September 2019 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
GKGagandeep Kaur
Gagandeep Kaur
RBRizwana Begum
Rizwana Begum
STShilpa Thota
Shilpa Thota
Sanjay BatraSanjay Batra
Sanjay Batra

28 February 2018 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
GKGagandeep Kaur
Gagandeep Kaur
RPRakeysha Pinkston
Rakeysha Pinkston
BMBenathel Mclemore
Benathel Mclemore
WDWaneene C. Dorsey
Waneene C. Dorsey
Sanjay BatraSanjay Batra
Sanjay Batra
Knowledge of the long-term toxicological and immunological effects of e-cigarette (e-cig) aerosols remains elusive due to the relatively short existence of vaping. Therefore, we performed a systematic search of articles published in public databases and analysed the research evidence in order to provide critical information regarding e-cig safety. Electronic nicotine delivery systems (or e-cigs) are an alternative to traditional cigarettes for the delivery of nicotine and are typically filled with glycerol or propylene glycol-based solutions known as e-liquids. Though present in lower quantities, e-cig aerosols are known to contain many of the harmful chemicals found in tobacco smoke. However, due to the paucity of experimental data and contradictory evidence, it is difficult to draw conclusive outcomes regarding toxicological, immunological and clinical impacts of e-cig aerosols. Excessive vaping has been reported to induce inflammatory responses including mitogen-activated protein kinase, Janus tyrosine kinase/signal transducer and activator of transcription and nuclear factor-κB signalling, similar to that induced by tobacco smoke. Based on recent evidence, prolonged exposure to some constituents of e-cig aerosols might result in respiratory complications such as asthma, chronic obstructive pulmonary disease and inflammation. Future studies are warranted that focus on establishing correlations between e-cig types, generations and e-liquid flavours and immunological and toxicological profiles to broaden our understanding about the effects of vaping.

9 March 2017 in Cell Biology and Toxicology
Verified
Journal Article
Closed access
PDF file
PBPrathyusha Bagam
Prathyusha Bagam
DSDhirendra Singh
Dhirendra Singh
MIMaria Eugenia Inda
Maria Eugenia Inda
Sanjay BatraSanjay Batra
Sanjay Batra

14 June 2016 in Immunology & Cell Biology
Verified
Journal Article
Open access
GKGagandeep Kaur
Gagandeep Kaur
Sanjay BatraSanjay Batra
Sanjay Batra
The immunoproteasome is a proteasome variant that is found only in jawed vertebrates. It is responsible for degrading intracellular proteins to generate a major source of peptides with substantial major histocompatibility complex I binding affinity. The immunoproteasome also has roles in T‐cell survival, differentiation and proliferation in various pathological conditions. In humans, any alteration in the expression, assembly or function of the immunoproteasome can lead to cancer, autoimmune disorders or inflammatory diseases. Although the roles of the immunoproteasome in cancer and neurodegenerative disorders have been extensively studied, its significance in other disease conditions has only recently become known. Therefore, there is renewed interest in the development of drugs, vaccines and biomarkers that target the immunoproteasome. The current review highlights the involvement of this complex in disease pathology in addition to the advances made in immunoproteasome research.